<article title='Antigen'><paragraph><link><target>Image:Antibody.svg</target><part>thumb</part><part>255px</part><trail>In</trail></link><space/><link><target>immunology</target></link>, an<space/><bold>antigen</bold><space/>(Ag) is any structural substance that serves as a target for the receptors of an adaptive immune response,<space/><link><target>T-cell receptor</target><part>TCR</part></link><space/>or<space/><link><target>B-cell receptor</target><part>BCR</part></link><space/>or its secreted form<space/><link><target>antibody</target></link>.<extension extension_name='ref'><template><target>cite book</target><arg name="title">Molecular Biology of the Cell<space/></arg><arg name="edition">4th<space/></arg><arg name="vauthors">Alberts B, Johnson A, Lewis J, et al.<space/></arg><arg name="location">New York<space/></arg><arg name="publisher">Garland Science<space/></arg><arg name="year">2002<space/></arg><arg name="url">http://www.ncbi.nlm.nih.gov/books/NBK21070/<space/></arg><arg name="chapter">24. The Adaptive Immune System<space/></arg></template></extension><space/>In simpler terms, an antigen is any substance that causes an immune system to produce antibodies against it.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.nlm.nih.gov/medlineplus/ency/article/002224.htm<space/></arg><arg name="title">Antigen<space/></arg><arg name="publisher">US National Library of Medicine</arg><arg name="accessdate">2015-07-30</arg></template></extension><space/>Each antibody is specifically selected after binding to a certain antigen because of<space/><link><target>V(D)J recombination</target><part>random somatic diversification</part></link><space/>in the antibody<space/><link><target>complementarity determining region</target><trail>s</trail></link>. A common analogy used to describe this is the fit between a lock and a key.</paragraph><paragraph>In summary an antigen is a<space/><link><target>molecule</target></link><space/>that binds to Ag-specific receptors, but cannot induce an immune response in the body by itself.<extension extension_name='ref' name="ReferenceA"><template><target>cite journal</target><arg name="last1">Gavin</arg><arg name="first1">AL</arg><arg name="last2">Hoebe</arg><arg name="first2">K</arg><arg name="last3">Duong</arg><arg name="first3">B</arg><arg name="last4">Ota</arg><arg name="first4">T</arg><arg name="last5">Martin</arg><arg name="first5">C</arg><arg name="last6">Beutler</arg><arg name="first6">B</arg><arg name="last7">Nemazee</arg><arg name="first7">D</arg><arg name="title">Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling.</arg><arg name="journal">Science</arg><arg name="date">22 December 2006</arg><arg name="volume">314</arg><arg name="issue">5807</arg><arg name="pages">1936–8</arg><arg name="pmid">17185603</arg><arg name="doi">10.1126/science.1135299</arg><arg name="pmc">1868398</arg></template></extension><space/>The term originally described a structural molecule that binds specifically to an antibody. It expanded to refer to any molecule or a linear molecular fragment that can be recognized by highly variable antigen receptors (<link><target>B-cell receptor</target></link><space/>or<space/><link><target>T-cell receptor</target></link>) of the adaptive immune system.</paragraph><paragraph>The antigen may originate from within the body (&quot;self-antigen&quot;) or from the external environment (&quot;non-self&quot;). The immune system usually does not react to self-antigens under normal<space/><link><target>homeostatic</target></link><space/>conditions due to<space/><link><target>Negative selection (immunology)</target><part>negative selection</part></link><space/>of<space/><link><target>T-cell</target><part>T cells</part></link><space/>in the<space/><link><target>thymus</target></link><space/>and is supposed to identify and attack only &quot;non-self&quot; invaders from the outside world or modified/harmful substances present in the body under<space/><link><target>Danger model</target><part>distressed conditions</part></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Gallucci</arg><arg name="first1">S</arg><arg name="last2">Lolkema</arg><arg name="first2">M</arg><arg name="last3">Matzinger</arg><arg name="first3">P</arg><arg name="title">Natural adjuvants: endogenous activators of dendritic cells.</arg><arg name="journal">Nature Medicine</arg><arg name="date">November 1999</arg><arg name="volume">5</arg><arg name="issue">11</arg><arg name="pages">1249–55</arg><arg name="pmid">10545990</arg><arg name="doi">10.1038/15200</arg></template></extension></paragraph><paragraph><link><target>Antigen presenting cell</target><trail>s</trail></link><space/>present antigens in the form of<space/><link><target>peptides</target></link><space/>on<space/><link><target>histocompatibility molecule</target><trail>s</trail></link>. The<space/><link><target>T cell</target><trail>s</trail></link><space/>of the<space/><link><target>adaptive immune system</target></link><space/>recognize the antigens. Depending on the antigen and the type of the histocompatibility molecule, different types of<space/><link><target>T cell</target><trail>s</trail></link><space/>activate. For<space/><link><target>T-cell receptor</target><part>T-Cell Receptor (TCR)</part></link><space/>recognition, the peptide must be processed into small fragments inside the cell and presented by a<space/><link><target>major histocompatibility complex</target></link><space/>(MHC).<extension extension_name='ref'>Parham, Peter. (2009). The Immune System, 3rd Edition, pg. G:2, Garland Science, Taylor and Francis Group, LLC.</extension><space/>The antigen cannot elicit the immune response without the help of an<space/><link><target>adjuvant</target><part>Immunologic adjuvant</part></link>.<extension extension_name='ref' name="ReferenceA"></extension><space/>Similarly, the adjuvant component of<space/><link><target>vaccines</target></link><space/>plays an essential role in the activation of the innate immune system.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Janeway CA</arg><arg name="first1">Jr</arg><arg name="title">Pillars article: approaching the asymptote? Evolution and revolution in immunology. Cold spring harb symp quant biol. 1989. 54: 1-13.</arg><arg name="journal">Journal of immunology (Baltimore, Md. : 1950)</arg><arg name="date">1 November 2013</arg><arg name="volume">191</arg><arg name="issue">9</arg><arg name="pages">4475–87</arg><arg name="pmid">24141854</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last">Gayed</arg><arg name="first">PM</arg><arg name="title">Toward a modern synthesis of immunity: Charles A. Janeway Jr. and the immunologist's dirty little secret.</arg><arg name="journal">The Yale journal of biology and medicine</arg><arg name="date">June 2011</arg><arg name="volume">84</arg><arg name="issue">2</arg><arg name="pages">131–8</arg><arg name="pmid">21698045</arg><arg name="pmc">3117407</arg><arg name="issn"><space/>1551-4056</arg></template></extension></paragraph><paragraph>An<space/><link><target>immunogen</target></link><space/>is a substance (or mixture) that is able to provoke a humoral and/or cell-mediated immune response.<extension extension_name='ref'>Parham, Peter. (2009). The Immune System, 3rd Edition, pg. G:11, Garland Science, Taylor and Francis Group, LLC.</extension><space/>It first initiates an<space/><link><target>innate immune system</target><part>innate immune response</part></link>, which causes the activation of the<space/><link><target>adaptive immune system</target><part>adaptive immune response</part></link>. An antigen binds the highly variable immunoreceptor products (<link><target>B-cell receptor</target></link><space/>or<space/><link><target>T-cell receptor</target></link>) once these have been generated. All immunogenic molecules are also antigenic, although the reverse is not true.<extension extension_name='ref'><template><target>cite book</target><arg name="title">Kuby Immunology<space/></arg><arg name="edition">6th<space/></arg><arg name="publisher">Macmillan<space/></arg><arg name="year">2006<space/></arg><arg name="pages">77<space/></arg><arg name="isbn">978-1-4292-0211-4<space/></arg></template></extension></paragraph><paragraph>At the molecular level, an antigen can be characterized by its ability to bind to an antibody's<space/><link><target>Fragment antigen-binding</target><part>variable Fab region</part></link>. Different antibodies have the potential to discriminate among specific<space/><link><target>epitope</target><trail>s</trail></link><space/>present on the antigen surface.<space/><link><target>Hapten</target></link><space/>is a small molecule that changes the structure of an antigenic epitope. In order to induce an immune response, it has to be attached to a large carrier molecule such as a<space/><link><target>protein</target></link>. Antigens are usually<space/><link><target>protein</target><trail>s</trail></link><space/>and<space/><link><target>polysaccharide</target><trail>s</trail></link>, and less frequently,<space/><link><target>lipid</target><trail>s</trail></link>. This includes parts (coats, capsules, cell walls, flagella, fimbrae, and toxins) of<space/><link><target>bacteria</target></link>,<space/><link><target>virus</target><trail>es</trail></link>, and other<space/><link><target>microorganism</target><trail>s</trail></link>.<space/><link><target>Lipid</target><trail>s</trail></link><space/>and<space/><link><target>nucleic acid</target><trail>s</trail></link><space/>are antigenic only when combined with proteins and polysaccharides.<template><target>citation needed</target><arg name="date">October 2012</arg></template><space/>Non-microbial non-self antigens can include pollen, egg white and proteins from transplanted tissues and organs or on the surface of transfused blood cells.<space/><link><target>Vaccine</target><trail>s</trail></link><space/>are examples of antigens in an immunogenic form, which are intentionally administered to induce the memory function of<space/><link><target>adaptive immune system</target></link><space/>toward the antigens of the pathogen invading the recipient.</paragraph><heading level='2'>Etymology</heading><paragraph><link><target>Paul Ehrlich</target></link><space/>coined the term<space/><link><target>Antibody#History</target><part>antibody</part></link><space/>(in German<space/><italics>Antikrper</italics>) in his<space/><link><target>side-chain theory</target></link><space/>at the end of 19th century.<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Strebhardt</arg><arg name="first">Klaus</arg><arg name="author2">Ullrich, Axel</arg><arg name="title">Paul Ehrlich's magic bullet concept: 100 years of progress</arg><arg name="journal">Nature Reviews Cancer</arg><arg name="date">Jun 2008</arg><arg name="volume">8</arg><arg name="issue">6</arg><arg name="pages">473–480</arg><arg name="doi">10.1038/nrc2394</arg><arg name="pmid">18469827</arg><arg name="issn">1474-1768</arg></template></extension><space/>In 1899,<space/><link><target>Lszl Detre (physician)</target><part>Ladislas Deutsch (Laszlo Detre)</part></link><space/>(18741939) named the hypothetical substances halfway between bacterial constituents and antibodies &quot;substances immunogenes ou antigenes&quot; (antigenic or immunogenic substances). He originally believed those substances to be precursors of antibodies, just as<space/><link><target>zymogen</target></link><space/>is a precursor of an enzyme. But, by 1903, he understood that an antigen induces the production of immune bodies (antibodies) and wrote that the word<space/><italics>antigen</italics><space/>is a contraction of antisomatogen (<italics>Immunkrperbildner</italics>). The Oxford English Dictionary indicates that the logical construction should be &quot;anti(body)-gen&quot;.<extension extension_name='ref' name="Lindenmann"><template><target>cite journal</target><arg name="author">Lindenmann, Jean<space/></arg><arg name="url">http://www3.interscience.wiley.com/cgi-bin/fulltext/119531625/PDFSTART<space/></arg><arg name="title">Origin of the Terms 'Antibody' and 'Antigen'<space/></arg><arg name="journal">Scand. J. Immunol.</arg><arg name="volume">19<space/></arg><arg name="pages">281–5<space/></arg><arg name="year">1984</arg><arg name="accessdate">2008-10-31<space/></arg><arg name="pmid">6374880<space/></arg><arg name="issue">4<space/></arg><arg name="doi">10.1111/j.1365-3083.1984.tb00931.x
</arg></template></extension></paragraph><heading level='2'>Terminology</heading><list type='bullet'><listitem><link><target>Epitope</target></link><space/>The distinct surface features of an antigen, its<space/><italics>antigenic determinant</italics>. Antigenic molecules, normally &quot;large&quot; biological polymers, usually present surface features that can act as points of interaction for specific antibodies. Any such feature constitutes an epitope. Most antigens have the potential to be bound by multiple antibodies, each of which is specific to one of the antigen's epitopes. Using the &quot;lock and key&quot; metaphor, the antigen can be seen as a string of keys (epitopes) each of which matches a different lock (antibody). Different antibody<space/><bold><link><target>idiotypes</target></link></bold>, each have distinctly formed<space/><link><target>complementarity determining region</target><trail>s</trail></link>.</listitem><listitem><link><target>Allergen</target></link><space/>A substance capable of causing an<space/><link><target>allergic reaction</target></link>. The (detrimental) reaction may result after exposure via ingestion, inhalation, injection, or contact with skin.</listitem><listitem><link><target>Superantigen</target></link><space/>A class of antigens that cause non-specific activation of T-cells, resulting in polyclonal T cell activation and massive<space/><link><target>cytokine</target></link><space/>release.</listitem><listitem><link><target>Tolerogen</target></link><space/>A substance that invokes a specific immune non-responsive due to its<space/><link><target>molecular form</target></link>. If its molecular form is changed, a tolerogen can become an immunogen.</listitem><listitem><link><target>Immunoglobulin</target></link>-binding protein Proteins such as<space/><link><target>Protein A</target></link>,<space/><link><target>protein G</target></link>, and<space/><link><target>protein L</target></link><space/>that are capable of binding to antibodies at positions outside of the antigen-binding site. While antigens are the &quot;target&quot; of antibodies, immunoglobulin-binding proteins &quot;attack&quot; antibodies. .</listitem><listitem>T-dependent antigen Antigens that require the assistance of T cells to induce the formation of specific antibodies.</listitem><listitem>T-independent antigen<space/><link><target>Polysaccharides</target></link><space/>(usually) that stimulate B cells directly.</listitem><listitem>Immunodominant antigens Antigens that dominate (over all others from a<space/><link><target>pathogen</target></link>) in their ability to produce an immune response. T cell responses typically are directed against a relatively few immunodominant epitopes, although in some cases (e.g., infection with the<space/><link><target>malaria</target></link><space/>pathogen<space/><italics><link><target>Plasmodium</target><part>Plasmodium spp.</part></link></italics>) it is dispersed over a relatively large number of parasite antigens.<extension extension_name='ref'><template><target>cite journal</target><arg name="title">Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data<space/></arg><arg name="authors">Doolan DL, Southwood S, Freilich DA, Sidney J, Graber NL, Shatney L, Bebris L, Florens L, Dobano C, Witney AA, Appella E, Hoffman SL, Yates JR 3rd, Carucci DJ, Sette A<space/></arg><arg name="journal">Proc Natl Acad Sci U.S.A.<space/></arg><arg name="date">August 19, 2003<space/></arg><arg name="volume">100<space/></arg><arg name="issue">17<space/></arg><arg name="pages">9952–9957<space/></arg><arg name="url">http://www.pnas.org/content/100/17/9952.full.pdf<space/></arg><arg name="doi">10.1073/pnas.1633254100<space/></arg></template></extension></listitem></list><heading level='2'>Sources</heading><paragraph>Antigens can be classified according to their source.</paragraph><heading level='3'>Exogenous antigens</heading><paragraph>Exogenous antigens are antigens that have entered the body from the outside, for example by<space/><link><target>inhalation</target></link>,<space/><link><target>ingestion</target></link><space/>or<space/><link><target>Injection (medicine)</target><part>injection</part></link>. The immune system's response to exogenous antigens is often subclinical. By<space/><link><target>endocytosis</target></link><space/>or<space/><link><target>phagocytosis</target></link>, exogenous antigens are taken into the<space/><link><target>antigen-presenting cell</target><trail>s</trail></link><space/>(APCs) and processed into fragments. APCs then present the fragments to<space/><link><target>T helper cells</target></link><space/>(<link><target>CD4</target></link><xhtml:sup>+</xhtml:sup>) by the use of<space/><link><target>MHC class II</target><part>class II histocompatibility</part></link><space/>molecules on their surface. Some T cells are specific for the peptide:MHC complex. They become activated and start to secrete<space/><link><target>cytokine</target><trail>s</trail></link>, substances that activate<space/><link><target>cytotoxic T lymphocytes</target></link><space/>(CTL), antibody-secreting<space/><link><target>B cells</target></link>,<space/><link><target>macrophages</target></link><space/>and other particles.</paragraph><paragraph>Some antigens start out as exogenontigens, and later become endogenous (for example, intracellular viruses). Intracellular antigens can be returned to circulation upon the destruction of the infected cell.</paragraph><heading level='3'>Endogenous antigens</heading><paragraph>Endogenous antigens are generated within normal cells as a result of normal cell<space/><link><target>metabolism</target></link>, or because of viral or intracellular bacterial<space/><link><target>infection</target></link>. The fragments are then presented on the cell surface in the complex with<space/><link><target>MHC class I</target></link><space/>molecules. If activated<space/><link><target>Cytotoxic T cell</target><part>cytotoxic CD8<xhtml:sup>+</xhtml:sup><space/>T cells</part></link><space/>recognize them, the T cells secrete various<space/><link><target>toxin</target><trail>s</trail></link><space/>that cause the<space/><link><target>lysis</target></link><space/>or<space/><link><target>apoptosis</target></link><space/>of the infected cell. In order to keep the cytotoxic cells from killing cells just for presenting self-proteins, the cytotoxic cells (self-reactive T cells) are deleted as a result of<space/><link><target>Central tolerance</target><part>tolerance</part></link><space/>(negative selection). Endogenous antigens include<space/><link><target>xenogenic</target></link><space/>(heterologous),<space/><link><target>autologous</target></link><space/>and<space/><link><target>idiotype</target><part>idiotypic</part></link><space/>or<space/><link><target>immunoglobulin allotype</target><part>allogenic</part></link><space/>(homologous) antigens.</paragraph><heading level='3'>Autoantigens</heading><paragraph>An<space/><link><target>autoantigen</target></link><space/>is usually a normal protein or protein complex (and sometimes DNA or RNA) that is recognized by the immune system of patients suffering from a specific<space/><link><target>autoimmune disease</target></link>. These antigens should not be, under normal conditions, the target of the immune system, but their associated T cells are not deleted and instead attack.</paragraph><heading level='3'>Neoantigens</heading><paragraph>Neoantigens are those that are entirely absent from the normal human genome. As compared with nonmutated self-antigens, neoantigens are of relevance to tumor control, as the quality of the T cell pool that is available for these antigens is not affected by central T cell tolerance. Technology to systematically analyze T cell reactivity against neoantigens became available only recently.<extension extension_name='ref' name="ss15"><template><target>cite journal</target><arg name="journal">Science<space/></arg><arg name="date"><space/>April 3, 2015<space/></arg><arg name="volume"><space/>348<space/></arg><arg name="issue"><space/>6230<space/></arg><arg name="pp"><space/>69–74<space/></arg><arg name="doi"><space/>10.1126/science.aaa4971<space/></arg><arg name="title">Neoantigens in cancer immunotherapy<space/></arg><arg name="first">Ton N.<space/></arg><arg name="last1">Schumacher1<space/></arg><arg name="first2">Robert D.<space/></arg><arg name="last2">Schreiber</arg></template></extension></paragraph><heading level='4'>Viral antigens</heading><paragraph>For virus-associated tumors, such as<space/><link><target>cervical cancer</target></link><space/>and a subset of<space/><link><target>head and neck cancers</target></link>,<space/><link><target>epitopes</target></link><space/>derived from viral open reading frames contribute to the pool of neoantigens.<extension extension_name='ref' name="ss15"></extension></paragraph><heading level='4'>Tumor antigens</heading><paragraph><italics><link><target>Tumor antigen</target><trail>s</trail></link></italics><space/>are those antigens that are presented by<space/><link><target>MHC I</target></link><space/>or<space/><link><target>MHC II</target></link><space/>molecules on the surface of<space/><link><target>tumor cell</target><trail>s</trail></link>. Antigens found only on such cells are called<space/><link><target>tumor-specific antigen</target><trail>s</trail></link><space/>(TSAs) and generally result from a tumor-specific<space/><link><target>mutation</target></link>. More common are antigens that are presented by tumor cells and normal cells, called<space/><link><target>tumor-associated antigen</target><trail>s</trail></link><space/>(TAAs).<space/><link><target>Cytotoxic T lymphocytes</target></link><space/>that recognize these antigens may be able to destroy tumor cells.<extension extension_name='ref' name="ss15"></extension></paragraph><paragraph>Tumor antigens can appear on the surface of the tumor in the form of, for example, a mutated receptor, in which case they are recognized by<space/><link><target>B cells</target></link>.<extension extension_name='ref' name="ss15"></extension></paragraph><paragraph>For human tumors without a viral etiology, novel<space/><link><target>peptides</target></link><space/>(neo-epitopes) are created by tumor-specific DNA alterations.<extension extension_name='ref' name="ss15"></extension></paragraph><heading level='5'>Process</heading><paragraph>A large fraction of human tumor mutations are effectively patient-specific. Therefore neoantigens may also be based on individual tumor genomes.<space/><link><target>Deep-sequencing</target></link><space/>technologies can identify mutations within the protein-coding part of the<space/><link><target>genome</target></link><space/>(the<space/><link><target>exome</target></link>) and predict potential neoantigens. In mice models, for all novel protein sequences, potential MHC-binding peptides were predicted. The resulting set of potential neoantigens was used to assess T cell reactivity. Exomebased analyses were exploited in a clinical setting, to assess reactivity in patients treated by either<space/><link><target>tumor-infiltrating lymphocyte</target></link><space/>(TIL) cell therapy or checkpoint blockade. Neoantigen identification was successful for multiple experimental model systems and human malignancies.<extension extension_name='ref' name="ss15"></extension></paragraph><paragraph>The false-negative rate of cancer exome sequencing is lowi.e., the majority of neoantigens occur within exonic sequence with sufficient coverage. However, the vast majority of mutations within expressed genes do not produce neoantigens that are recognized by autologous T cells.<extension extension_name='ref' name="ss15"></extension></paragraph><paragraph>As of 2015 mass spectroscopy resolution is insufficient to exclude many false positives from the pool of peptides that may be presented by MHC molecules. Instead, algorithms are used to identify the most likely candidates. These algorithms consider factors such as the likelihood of<space/><link><target>proteasome</target><part>proteasomal</part></link><space/>processing, transport into the<space/><link><target>endoplasmic reticulum</target></link>, affinity for the relevant MHC class I<space/><link><target>alleles</target></link><space/>and gene expression or protein translation levels.<extension extension_name='ref' name="ss15"></extension></paragraph><paragraph>The majority of human neoantigens identified in unbiased screens display a high predicted MHC binding affinity. Minor histocompatibility antigens, a conceptually similar antigen class are also correctly identified by MHC binding algorithms. Another potential filter examines whether the mutation is expected to improve MHC binding. The nature of the central TCR-exposed residues of MHC-bound peptides is associated with peptide immunogenicity.<extension extension_name='ref' name="ss15"></extension></paragraph><heading level='3'>Nativity</heading><paragraph>A native antigen is an antigen that is not yet processed by an APC to smaller parts.<space/><link><target>T cells</target></link><space/>cannot bind native antigens, but require that they be processed by APCs, whereas<space/><link><target>B cells</target></link><space/>can be activated by native ones.</paragraph><heading level='2'>Antigenic specificity</heading><paragraph>Antigenic specificity is the ability of the host cells to recognize an antigen specifically as a unique molecular entity and distinguish it from another with exquisite precision. Antigen specificity is due primarily to the side-chain conformations of the antigen. It is measurable and need not be linear or of a rate-limited step or equation.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.steadyhealth.com/encyclopedia/Antigen_specificity<space/></arg><arg name="title">Antigen specificity - Medical Terms<space/></arg><arg name="publisher">Steadyhealth.com<space/></arg><arg name="date">2010-12-17<space/></arg><arg name="accessdate">2012-07-08</arg></template></extension></paragraph><heading level='2'>See also</heading><paragraph><template><target>columns-list</target><arg>3</arg><arg>
* [[Antitoxin]]
* [[Conformational epitope]]
* [[Epitope]]
* [[Linear epitope]]
* [[Magnetic immunoassay]]
* [[Neutralizing antibody]]
* [[Original antigenic sin]]
* [[Paul Ehrlich]]: Magic Bullet
* [[Polyclonal B cell response]]
* [[Priming (immunology)]]
</arg></template></paragraph><heading level='2'>Notes</heading><paragraph><template><target>Reflist</target><arg>30em</arg></template></paragraph><heading level='2'>External links</heading><list type='bullet'><listitem><link type='external' href='http://www.histochem.net/histochemistry%20protocol%20antigen%20retrieval.htm'>Antigen Retrieval Protocol</link></listitem><listitem><link type='external' href='http://www.nlm.nih.gov/medlineplus/ency/article/002224.htm'>National Library of Medicine/Medline (National Institute of Health) website</link></listitem></list><paragraph><template><target>immune system</target></template></paragraph><paragraph><link><target>Category:Immune system</target></link><link><target>Category:Biomolecules</target></link></paragraph></article>